These compounds may interact with:
Endothelial PAS domain-containing protein 1
Potentially involved in: primary polycythemia; kidney cancer; carcinoma; polycythemia; persistent generalized lymphadenopathy; cancer; renal cell carcinoma; neoplastic cell transformation; chromosome aberrations; hematocrit increased; hemoglobin increased; erythrocytosis, familial, 4; adrenocortical carcinoma; atypical teratoid / rhabdoid tumor; breast carcinoma; copd; ductal carcinoma in situ; intraductal papillary-mucinous neoplasm (ipmn); invasive ductal carcinoma; lung adenocarcinoma
Disease data sourced from Pharos.